Clinical Trials
11 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03493451 2024-10-26
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Phase 2 Completed
NCT03947255 2023-10-13
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT02939014 2021-02-24
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Takeda
Phase 2 Completed
NCT04306887 2020-03-13
A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated
NCT00866047 2017-03-22
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00947856 2017-02-02
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Seagen Inc.
Phase 2 Completed
NCT00079755 2014-12-18
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Seagen Inc.
Phase 2 Completed
NCT00298467 2010-04-26
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Bristol-Myers Squibb
Phase 2 Withdrawn